Cordis Corporation v. Medtronic, Inc.

780 F.2d 991, 86 A.L.R. Fed. 445, 228 U.S.P.Q. (BNA) 189, 1985 U.S. App. LEXIS 15529
Court of Appeals for the Federal Circuit·Decided December 17, 1985·No. Appeal 85-1987·Published·Cited by 27 cases

Opinion

BISSELL, Circuit Judge.

This appeal is from the Order of the District Court for the Southern District of Florida, No. 84-2479-CIV-Atkins, (January 10, 1985), 606 F.Supp. 132, granting the motion for relief pendente lite of Cordis Corporation (Cordis):

(a) permitting Cordis to deposit into an escrow account all future royalty payments due Medtronic, Inc. (Med-tronic) pursuant to the license agreement between the parties; and
(b) enjoining Medtronic from terminating the license agreement because of Cordis’ failure to make royalty payments pursuant to the agreement. This in effect protects Cordis from patent infringement or breach of contract counterclaims.

The issuance of the Order by the district court is vacated. The motion for relief pendente lite is remanded for further consideration not inconsistent with this opinion.

I

Cordis filed suit against Medtronic seeking a declaratory judgment that the two licensed Medtronic patents, U.S. Patent Nos. 3,902,501 (’501) and 3,939,843 (’843), are invalid (Count I of the Complaint) and that the license agreement between Cordis and Medtronic “is void in its inception” (Count II of the Complaint). Contemporaneous with filing of the declaratory judgment action, Cordis moved for an order to establish a court escrow account into which the royalty payments due Medtronic, pen-dente lite, would be deposited. Additionally, Cordis sought a preliminary injunction to enjoin Medtronic from terminating the license agreement during the pendency of the patent invalidity suit.

The district court, relying on Precision Shooting Equipment Co. v. Allen, 646 F.2d 313, 210 USPQ 184 (7th Cir.), cert. denied, 454 U.S. 964, 102 S.Ct. 503, 70 L.Ed.2d 379 (1981), and Atlas Chemical Industries, Inc. v. Moraine Products, 509 F.2d 1, 184 USPQ 281 (6th Cir.1974), granted the motion and permitted Cordis to deposit any royalty payments due Medtronic pendente lite into an interest bearing escrow account, with all funds accumulated in the escrow account to be paid to the prevailing party. The district court enjoined Medtronic from terminating the license agreement during the pendency of the action.

Consequently, the issue on appeal to this court is whether the district court properly granted the preliminary injunction and Cor-dis’ motion for establishment of the escrow account.

II

Our jurisdiction over this appeal arises under 28 U.S.C. § 1292(a)(1) and (c) which permits interlocutory appeals from trial court orders granting injunctions. Because a portion of the district court’s interlocutory order enjoins Medtronic from terminating the license agreement, we have jurisdiction over the whole order, including the portion establishing a court escrow account for depositing royalty payments. *994 Jaffee v. United States, 592 F.2d 712 (3d Cir.1979), on remand, 468 F.Supp. 632 (D.N.J.1979), cert. denied, 441 U.S. 961, 99 S.Ct. 2406, 60 L.Ed.2d 1066 (1979), aff’d, 663 F.2d 1226 (3d Cir.1981), cert. denied, 456 U.S. 972,102 S.Ct. 2234, 72 L.Ed.2d 845 (1982); see also United States v. Connolly, 716 F.2d 882, 885 (Fed.Cir.1983) (Under 28 U.S.C. § 1292(d)(2), this court’s scope of review is not limited to the certified question. We can consider all questions material to the correctness of the interlocutory order.)

III

The Supreme Court, in Lear, Inc. v. Adkins, 395 U.S. 653, 671, 89 S.Ct. 1902, 1911, 23 L.Ed.2d 610, 162 USPQ 1, 8 (1969), held that a licensee to a patent license agreement is not estopped from contesting the validity of the patent subject to the agreement. Lear further held that licensees cannot be required to continue to pay royalties during the time they are challenging patent validity in the courts. Id. at 673, 89 S.Ct. at 1912, 162 USPQ at 9. In C.R. Bard, Inc. v. Schwartz, 716 F.2d 874, 219 USPQ 197 (Fed.Cir.1983), this court held that a patent licensee may seek a federal declaratory judgment to declare a patent, subject to a license, invalid without prior termination of the license.

It is well settled that the purpose of an interlocutory injunction is to preserve the status quo and to protect the respective rights of the parties pending a determination on the merits. Atlas Powder Co. v. Ireco Chemicals, 773 F.2d 1230, 227 USPQ 289 (Fed.Cir.1985); Smith International, Inc. v. Hughes Tool Co., 718 F.2d 1573, 219 USPQ 686 (Fed.Cir.), cert. denied, 464 U.S. 996, 104 S.Ct. 493, 78 L.Ed.2d 687, 220 USPQ 385 (1983); accord Cate v. Oldham, 707 F.2d 1176 (11th Cir.1983). The status of these parties before the district court is that of a patentee-licensor of two patents, each presumptively valid pursuant to 35 U.S.C. § 282, and that of a licensee of those patents.

This court exercises a very narrow scope of review over the district court’s grant of injunctive relief. Smith International, 718 F.2d at 1579, 219 USPQ at 691. The district court’s determination can be overturned only upon a showing that it abused its discretion, committed an error of law, or seriously misjudged the evidence. Rogers v. Hill, 289 U.S. 582, 587, 53 S.Ct. 731, 733, 77 L.Ed. 1385 (1933); National File Ins. Co. v. Thompson, 281 U.S. 331, 338, 50 S.Ct. 288, 291, 74 L.Ed. 881 (1930); Meccano, Ltd. v. John Wanamaker, 253 U.S. 136, 141, 40 S.Ct. 463, 465, 64 L.Ed. 822 (1920); Smith International, 718 F.2d at 1579, 219 USPQ at 691.

Free access — add to your briefcase to read the full text and ask questions with AI

Cordis Corporation v. Medtronic, Inc., 780 F.2d 991, 86 A.L.R. Fed. 445, 228 U.S.P.Q. (BNA) 189, 1985 U.S. App. LEXIS 15529 (Fed. Cir. 1985).

780 F.2d 991 (Cordis Corporation v. Medtronic, Inc.) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Cellport Systems, Inc. v. Peiker Acustic GMBH & Co. KG
916 F. Supp. 2d 1212 (D. Colorado, 2013)
Broadcom Corp. v. Qualcomm Inc.
585 F. Supp. 2d 1187 (C.D. California, 2008)
MedImmune, Inc. v. Genentech, Inc.
535 F. Supp. 2d 1000 (C.D. California, 2008)
Medimmune, Inc. v. Genentech, Inc.
427 F.3d 958 (Federal Circuit, 2005)
Medimmune v. Centocor
Federal Circuit, 2005
MedImmune, Inc. v. Centocor, Inc.
409 F.3d 1376 (Federal Circuit, 2005)
Medimmune, Inc. v. Centocor, Inc.
409 F.3d 1376 (D.C. Circuit, 2005)
Bayer AG v. Housey Pharmaceuticals, Inc.
228 F. Supp. 2d 467 (D. Delaware, 2002)
Newby v. Enron Corp.
188 F. Supp. 2d 684 (S.D. Texas, 2002)
Ballas v. Tedesco
41 F. Supp. 2d 531 (D. New Jersey, 1999)
Eli Lilly and Co. v. American Cyanamid Co.
896 F. Supp. 851 (S.D. Indiana, 1995)
Dow Chemical Co. v. United States
39 Cont. Cas. Fed. 76,704 (Federal Claims, 1994)
Value Group, Inc. v. Mendham Lake Estates, L.P.
800 F. Supp. 1228 (D. New Jersey, 1992)
Foster v. Hallco Manufacturing Co.
24 Cl. Ct. 469 (Federal Circuit, 1991)